{"id":"tr-701-fa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TR-701 FA (tedizolid phosphate) is rapidly converted to TR-700 (tedizolid) in vivo. TR-700 is an oxazolidinone antibiotic that binds to the bacterial 70S ribosome and inhibits protein synthesis, making it effective against gram-positive bacteria including multidrug-resistant pathogens. It has enhanced potency and improved pharmacokinetics compared to linezolid, the parent oxazolidinone class drug.","oneSentence":"TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:25.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Community-acquired bacterial pneumonia (CABP)"}]},"trialDetails":[{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT06733688","phase":"PHASE1","title":"A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-23","conditions":"Healthy","enrollment":36},{"nctId":"NCT02750761","phase":"PHASE1","title":"A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Gram-Positive Bacterial Infections","enrollment":32},{"nctId":"NCT01271998","phase":"PHASE1","title":"Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-12-08","conditions":"Bacterial Infection","enrollment":20},{"nctId":"NCT02019420","phase":"PHASE3","title":"Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-01-06","conditions":"Pneumonia","enrollment":726},{"nctId":"NCT01156077","phase":"PHASE1","title":"Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-02","conditions":"Bacterial Infection","enrollment":20},{"nctId":"NCT01461460","phase":"PHASE1","title":"A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-11-28","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT01519778","phase":"PHASE2","title":"A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-02-15","conditions":"Major Cutaneous Abscess, Cellulitis, Erysipelas","enrollment":200},{"nctId":"NCT01170221","phase":"PHASE3","title":"TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-08-15","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":667},{"nctId":"NCT01421511","phase":"PHASE3","title":"TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-09-15","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":666},{"nctId":"NCT01577459","phase":"PHASE1","title":"A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-04-23","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT01623401","phase":"PHASE1","title":"A Phase 1, Open-Label, 10 Day Safety Study","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-05-17","conditions":"Healthy Subjects","enrollment":72},{"nctId":"NCT01496677","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-01-17","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT01431833","phase":"PHASE1","title":"A PK and Safety Study in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-08","conditions":"Hepatic Impairment","enrollment":32},{"nctId":"NCT00983255","phase":"PHASE1","title":"Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-09","conditions":"Bacterial Infections","enrollment":90},{"nctId":"NCT01452828","phase":"PHASE1","title":"A Pharmacokinetics and Safety Study in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-10","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT01539473","phase":"PHASE1","title":"A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-02","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tedizolid Phosphate","TR-700 active moiety","Tedizolid"],"phase":"phase_3","status":"active","brandName":"TR-701 FA","genericName":"TR-701 FA","companyName":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"trius-therapeutics-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}